Results 101 to 110 of about 263,159 (256)

Age effect on retina and optic disc normal values [PDF]

, 2005
Purpose: To investigate retinal thickness and optic disc parameters by the Retinal Thickness Analyzer (RTA) glaucoma program in older normal subjects and to determine any age effect.
Chryssafis, C., Hirneiß, Christoph, Neubauer, A. S., Tsinopoulos, I., Kampik, Anselm, Thiel, M.   +5 more
core   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Optic Glioma in Children A Retrospective Analysis of 101 Cases

, 2013
Aim: To evaluate the clinical characteristics and long-term outcome of pediatric patients with optic ...
Akalan, NEJAT, SOYLEMEZOGLU, Figen, AKYÜZ, CANAN, ZORLU, Faruk, BATU, Abduselam, Buyukpamukcu, MÜNEVVER, BALCI, Serdar, VARAN, ALİ, CILA, Aysenur, KUTLUK, Tezer   +9 more
core   +1 more source

Patient‐reported outcomes and medication errors during oral antitumour therapy in paediatrics: Results from the youngAMBORA care programme

British Journal of Clinical Pharmacology, EarlyView.
Aim Increasing use of oral antitumour therapeutics (OAT) in paediatrics is associated with numerous advantages, but also with error‐prone aspects. Based on the randomized AMBORA trial including adults treated with various OAT, we developed a tailored pharmacological/pharmaceutical care programme for children and their caregivers during OAT treatment ...
Phyllis Lensker, Lisa Cuba, Frank Dörje, Martin F. Fromm, Markus Metzler   +4 more
wiley   +1 more source

F2b14 Progression of Optic Disc Changes Caused by Malignant Optic Nerve Glioma of Adulthood

, 1992
Progression. Group with F2b_12_1 and F2b_13_2. 69 year old male. Shows signs of myelin being squeezed through the optic disc into the eye. June 6, 1992. Reference: Hoyt WF, Meshel LG, Lessell S, Schatz NJ, Suckling RD.
William F. Hoyt, MD
core  

Overall Survival for the whole population with optic pathway glioma.

, 2015
Overall Survival for the whole population with optic pathway glioma.
Jacques Grill (87832), Josué Rakotonjanahary (758404), Emilie De Carli (758405), François Doz (2541151), Chantal Kalifa (87830), Anne-Isabelle Bertozzi (758407), Xavier Rialland (596848), Matthieu Delion (758406), Pierre Leblond (91850)   +8 more
core   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

NF1 mutation drives neuronal activity-dependent initiation of optic glioma. [PDF]

Nature, 2021
Pan Y, Hysinger JD, Barron T, Schindler NF, Cobb O, Guo X, Yalçın B, Anastasaki C, Mulinyawe SB, Ponnuswami A, Scheaffer S, Ma Y, Chang KC, Xia X, Toonen JA, Lennon JJ, Gibson EM, Huguenard JR, Liau LM, Goldberg JL, Monje M, Gutmann DH.   +21 more
europepmc   +1 more source

F2b13 Progression of Optic Disc Changes Caused by Malignant Optic Nerve Glioma of Adulthood

, 1992
Progression. Group with F2b_12_1 and F2b_14_3. 69 year old male. April 22, 1992. There are signs of CVRO. Reference: Hoyt WF, Meshel LG, Lessell S, Schatz NJ, Suckling RD. Malignant optic glioma of adulthood. Brain. 1973;96(1):121-32. Anatomy: Optic disc.
William F. Hoyt, MD
core  

Glycosylated dendrimer nanoamplifiers hijack DNA damage‐immune crosstalk for enhanced dual‐track therapy of orthotopic glioblastoma

BMEMat, EarlyView.
A glycosylated dendrimer nanoamplifier hijacks DNA damage‐immune crosstalk for enhanced radio‐immunotherapy of glioblastoma. The responsive release of demethylcantharidin simultaneously blocks repair‐mediated resistance by inhibiting DNA repair and overcomes adaptive immune resistance.
Cong Song, Binghan Liu, Junjie Liu, Ce Li, Wenqing Man, Xurui Sun, Chang Yuan, Yanjun Wang, Hong Pan, Shuanglian Wang, Zhiming Zheng   +10 more
wiley   +1 more source